<DOC>
	<DOCNO>NCT00781755</DOCNO>
	<brief_summary>This clinical research protocol study efficacy combine varenicline ( Chantix ) motivational interviewing ( MI ) smoke cessation sample smoker diagnose schizophrenia schizoaffective disorder . The study double-blind , randomize , control , subacute treatment trial MI plus varenicline ( VAR-MI ) versus MI plus placebo ( PLA-MI ) . The pharmaceutical treatment utilize Chantix dose 1 mg/day period two week . The primary goal determine VAR-MI decrease baseline behavioral measure urge withdrawal reduces baseline rate cigarette consumption . The primary efficacy measure VAR-MI vs. PLA-MI treatment : Minnesota Nicotine Withdrawal Scale , Questionnaire Smoking Urge-brief , number cigarette smoke per day previous week , CO level , Brief Psychiatric Rating Scale Positive And Negative Symptom Scale score last day study . Other primary outcome measure determine effect VAR-MI PLA-MI smoking cue-induced urge tobacco cue reactivity session reward responsiveness assess computerized task .</brief_summary>
	<brief_title>Treating Schizophrenic Smokers : Effects Craving , Cues Withdrawal</brief_title>
	<detailed_description />
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Eligible participant study : Are age 1865 year age Are daily cigarette smoker Have smoke minimum 10 cigarette per day least one year Are confirm smoker verify CO Have psychiatric diagnosis schizophrenia schizoaffective disorder ( subtype ) determine SCIDIV . Participants must receive stable dose antipsychotic medication least 2 week prior begin study . Patients receive clozapine 500 mg/day must also receive antiseizure prophylaxis . Patients must determine psychiatrically stable baseline establish standardize interview medical review psychiatrist . Individuals eligible participate study include individual : Any serious unstable medical problem last 6 month Severe renal impairment A history clinically significant allergic reaction nicotine agonist medication Current primary use tobacco product cigarettes Breath alcohol level &gt; 0.005 g/l screen Current substance abuse dependence ( besides nicotine ) Current attempt quit smoke use method Designation legally incompetent sign inform consent ( i.e. , guardian delegate power attorney another ) . Other exclusion : Current use medication might affect behavioral response cigarette smoking , include transdermal nicotine nicotine gum bupropion Inability participate screening session due severe psychosis , severe depression suicidality , current mania , organic mental disorder dementia delirium Presence unstable psychiatric symptom clinical deterioration ( i.e. , unstable psychosis , homicidality , suicidality ) within last month . Females childbearing potential eligible pregnant nursing practice effective contraception ( oral , injectable , implantable contraceptive ; intrauterine device ; barrier method spermicide ) . There currently know contraindication use varenicline identify drugdrug interaction . However , reduce dosage varenicline recommend individual severe renal impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>smoke cessation</keyword>
	<keyword>varenicline</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>serious mental illness</keyword>
	<keyword>Nicotine addiction</keyword>
	<keyword>Smoking Behavior</keyword>
</DOC>